Tu Hong Biotech

Tuhong Biotech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on developing first-in-class and best-in-class small molecule drugs for cancer treatment. The company utilizes a sophisticated structure-based drug discovery (SBDD) platform to tackle difficult-to-drug targets, particularly those involved in the RAS/MAPK signaling pathway. Its lead candidate, TH-001, is a highly selective SOS1 inhibitor currently in Phase 1 clinical trials for patients with advanced solid tumors harboring KRAS mutations. Tuhong's broader pipeline includes inhibitors for KRAS G12D and SHP2, reflecting its commitment to addressing unmet needs in precision oncology. The company is backed by prominent venture capital firms including Matrix Partners China and Qiming Venture Partners. By integrating structural biology with medicinal chemistry, Tuhong aims to deliver innovative therapies for patients with limited treatment options.